ARTICLE | Company News
EpiCept, GNI Ltd. deal
July 21, 2008 7:00 AM UTC
GNI received a license to develop and commercialize EpiCept’s EP1013 for late-stage viral hepatitis in Asia, Australia and New Zealand. The small molecule inhibitor of caspases is in preclinical deve...